Deflazacort
Modify Date: 2024-01-02 17:07:17
Deflazacort structure
|
Common Name | Deflazacort | ||
|---|---|---|---|---|
| CAS Number | 14484-47-0 | Molecular Weight | 441.517 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 595.4±50.0 °C at 760 mmHg | |
| Molecular Formula | C25H31NO6 | Melting Point | 255-256.5ºC | |
| MSDS | Chinese USA | Flash Point | 313.9±30.1 °C | |
Use of DeflazacortDeflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.Target: Glucocorticoid ReceptorDeflazacort is an inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort. Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h. The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h. 21-Desacetyldeflazacort was cleared significantly faster than both methylprednisolone and prednisolone [1]. Two of 40 boys treated with deflazacort died at 13 and 18 years of age from cardiac failure. The treated boys were significantly shorter, did not have excessive weight gain and 22 of 40 had asymptomatic cataracts. Deflazacort has a very significant impact on health, quality of life and health care costs for boys with DMD and their families, and is associated with few side effects [2]. |
| Name | Deflazacort |
|---|---|
| Synonym | More Synonyms |
| Description | Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.Target: Glucocorticoid ReceptorDeflazacort is an inactive prodrug which is converted rapidly to the active metabolite 21-desacetyldeflazacort. Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h. The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h. 21-Desacetyldeflazacort was cleared significantly faster than both methylprednisolone and prednisolone [1]. Two of 40 boys treated with deflazacort died at 13 and 18 years of age from cardiac failure. The treated boys were significantly shorter, did not have excessive weight gain and 22 of 40 had asymptomatic cataracts. Deflazacort has a very significant impact on health, quality of life and health care costs for boys with DMD and their families, and is associated with few side effects [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 595.4±50.0 °C at 760 mmHg |
| Melting Point | 255-256.5ºC |
| Molecular Formula | C25H31NO6 |
| Molecular Weight | 441.517 |
| Flash Point | 313.9±30.1 °C |
| Exact Mass | 441.215149 |
| PSA | 102.26000 |
| LogP | 2.02 |
| Vapour Pressure | 0.0±3.8 mmHg at 25°C |
| Index of Refraction | 1.661 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
![3β-hydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazole-11,20-dione 20-semicarbazone Structure](https://www.chemsrc.com/caspic/112/16119-50-9.png)
CAS#:16119-50-9
CAS#:13649-88-2![3β-acetoxy-11β-hydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazol-20-one Structure](https://www.chemsrc.com/caspic/127/13649-87-1.png)
CAS#:13649-87-1![21-hydroxy-2'-methyl-16-β-5'H-pregna-1,4,9(11)-trieno[17,16-d]oxazole-3,20-dione 21-acetate Structure](https://www.chemsrc.com/caspic/374/16119-56-5.png)
CAS#:16119-56-5
CAS#:13649-57-5| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.
Pediatrics 130(6) , e1559-66, (2012) The purpose of this study was to assess health-related quality of life (QoL) in children with Duchenne muscular dystrophy (DMD), including development and field-testing of a DMD-specific module integr... |
|
|
Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
Muscle Nerve 45(6) , 796-802, (2012) Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion.We performed a long-te... |
|
|
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.
Orphanet J. Rare Dis. 8 , 26, (2013) Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with th... |
| Deflazacort |
| 2-[(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-Hydroxy-4a,6a,8-trimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-6b-yl]-2-oxoethyl acetate |
| 11b,21-Dihydroxy-2'-methyl-5'bH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate |
| Pregna-1,4-diene-11b,21-diol-3,20-dione[17a,16a-d]-2'-methyloxazoline 21-Acetate |
| Calcort |
| DL 458-IT |
| (11b,16b)-21-(Acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione |
| Dezacor |
| Lantadin |
| Cortax,Decortil,Deflanil |
| Deflan |
| 2H-Naphth[2',1':4,5]indeno[1,2-d]oxazol-2-one, 6b-[2-(acetyloxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-5-hydroxy-4a,6a,8-trimethyl-, (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)- |
| Flantadin |
| EINECS 238-483-7 |
| Azacort |